Obligatory Legal Disclaimer:  This research information is provided for personal educational purposes only, and does not constitute a medical claim for any product of any nature whatsoever.  Consult a qualified healthcare practitioner for the diagnosis and treatment of any disease, ailment or medical condition. These Statements have not been approved by the FDA.

Cancell, Cantron or Procell and Taxol

Cancell, now sold as Cantron or Procell

History

Cancell was introduced by James V. Sheridan, a biochemist who named the formula Entelev and gave it free to cancer patients. Entelev is the name of the original formula.   James V. Sheridan, a chemist and researcher from Michigan.,  developed the concept for his formulation in 1936.  He conducted  animal studies in the late 40's, attempted  clinical trials in the 50's while working for the Michigan Cancer Institute, and in the early 60's, he conducted further research while working with Battelle Laboratories (the testing center for the National Cancer Institute). Between 1974 and 1983 Mr. Sheridan gave the formula away at no charge to over one thousand people.   He always refused financial compensation for Cancell, saying it was a gift from God and should be distributed to anyone needing it.
 

Sheridan gave his formula to Don  Wilson in 1983 Shortly thereafter, in May of 1983, the FDA issued Sheridan with a cease and desist order to stop him from distributing Entelev.  Sheridan had made medical claims for his product, which he was not allowed to do.  Sheridan and Wilson teamed up with Jerome Godin of Medical Research Products, and in 1984 the product was re-released under the name Cantron.   The company was affiliated with two chemists named Orz Feather and Ed Sopcak, who refined the manufacturing process.  Sopcak started making a small amount of the formula on his own in 1985 under the name Cancell and gave it away for free to patients.

The original *Cancell was based on the  dark liquid formulation of James Sheridan. Cancell" is a registered Trademark of Mary Sahs and Susan Sopcak, which was filed in May of 2001  I n 1991-1992 after almost 8 years of manufacturing and donating  an estimated 30,000 bottles of Cancell, Mr. Sopcak  changed the formula to produce a clear liquid,  which he referred to as Clear Cancell.  Later the clear product became known as Quantrol, while the original, dark formula became known as Dark *Cancell.  The change in coloration was due to a lower quantity of cyclopentene.  Both the new and old formulas worked well, according to patients, but Godin later changed the formula to re-include the cyclopentene, since he believed it had important properties.

Neither Cancell or Quantrol are presently being distributed anywhere in the world as they are subject to a federal permanent injunction.

Cantron is still being sold by Medical Research Products, and has not yet been targeted by the FDA as it is offered only as a dietary supplement, specifically for its electrolyte and antioxidant properties as well as for its role in the cellular respiration system.

Method of Action

Cantron works by reducing the ATP energy (adenosine triphosphate) in each cell. Cells have an electrical potential affecting how the cell processes energy producing substances mostly blood sugar and oxygen from our blood supply. By reducing this voltage level from 70 to 110 mv to approximatley the 50 mv region, normal cells can still function. However, cancer and viral cells cannot process energy at this low voltage level and start to starve. The process of starving cancer cells is a slower process than poisoning which is why this product works more slowly than the direct cellular toxins used in  chemotherapy.

Clinical Tests

In a two days test run by the NCI there was a dramatic reduction in the weight of tumor cells but only a small number of dead cells.  Presumably, if the test had continued longer, the shrunken cells would have starved to death.  However, the  NCI test for cancer therapy agents is designed specifically for fast acting chemotherapy drugs which kill tumor cells immediately.  Slow acting Cancell reduced the mass of half of the 60 tumors tested by 80% or more in just two days. Such results are spectacular, but in their summary NCI reported "negative results" to describe the test despite the fact that tumor weight data takes up 8 of the 14 columns on the NCI test data sheets.   In fact, it performed better than Taxol, the recognized "gold standard chemotherapeutic agent.

The table below shows the test result of perillyl alcohol (an inactive compound used as a control substance), taxol and cancell.  The figures in the table correspond to tumor cell mass reduction.